Nymox Pharmaceutical Corp (NASDAQ:NYMX)
| 5.15 Data as of May 17 |  +0.10 / +1.98%Today’s Change | 4.20 Today|||52-Week Range 8.53 | -24.93% Year-to-Date |
Latest NYMX News | Press Releases
No recent news for Nymox Pharmaceutical Corp.
Today’s Trading
| Previous close | 5.05 |
| Today’s open | 5.03 |
| Day’s range | 4.95 - 5.18 |
| Volume | 36,380 |
| Average volume (3 months) | 83,985 |
| Market cap | $173.7M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/17/2013
Growth & Valuation
| Earnings growth (last year) | +23.33% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -1.32% |
| P/E ratio | NM |
| Price/Sales | 74.07 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CORTCorcept Therapeutics... | +0.01 | +0.58% |
| PRTAProthena Corporation... | +0.53 | +5.68% |
| OMTHOmthera Pharmaceutic... | -0.23 | -3.15% |
| ARQLArQule Inc | +0.02 | +0.72% |
Data as of 4:00pm ET, 05/17/2013
Financials
| Last reporting date | May 14, 2013 |
| EPS forecast (this quarter) | -$0.04 |
| Annual revenue (last year) | $3.1M |
| Annual profit (last year) | -$7.6M |
| Net profit margin | -248.25% |
Profile
Sector Health Technology |
Industry Medical Specialties |
Chairman, President & Chief Executive Officer Paul Averback, MD |
Chief Financial Officer, Secretary & Treasurer Roy M. Wolvin |
Corporate headquarters Saint-Laurent, Québec |
Forecasts
